CCO Official Conference Coverage: Clinical Impact of New HIV Data From AIDS 2022

Download All
July 29-August 2, 2022; Montreal, Quebec
Engage in this scientific analysis of data presented at AIDS 2022, with rapid postconference webinars by expert faculty and Capsule Summaries on key HIV prevention, treatment studies,and new and investigational ART regimens. Watch the on-demand webinars, download the slides, and gain global perspectives with companion ClinicalThought commentaries.


Capsule Summary Slidesets

Gender-affirming hormonal therapy did not appear to affect cabotegravir concentrations in transgender women in this preliminary analysis from HPTN 083.

Released: August 1, 2022

Both DTG 50 mg plus 3TC/TDF and EFV 400 mg plus 3TC/TDF regimens effective and safe for treatment-naive PWH in Cameroon, with higher rates of virologic suppression over time and more weight gain observed with DTG-based regimen.

Released: August 2, 2022

Switching from standard combination ART to DTG plus FTC was noninferior to continuing standard combination ART in virologically suppressed adults through Week 144 in this randomized clinical trial.

Released: August 2, 2022

Significantly greater proportion of patients with HIV/HBV coinfection achieved HBV DNA <29 IU/mL with BIC/FTC/TAF vs DTG + FTC/TDF at 48 weeks; HIV outcomes were similar with both regimens.

Released: August 3, 2022

Dual therapy was well tolerated and demonstrated noninferior efficacy vs triple therapy as first-line ART in this open-label, randomized trial conducted in Argentina.

Released: August 5, 2022

Bedaquiline, pretomanid, and linezolid with or without clofazimine or moxifloxacin for 24 weeks appeared to be generally safe and effective for the treatment of rifampicin-resistant TB in both people with and without HIV in this randomized, open-label phase II/III trial.

Released: August 4, 2022

PrEP adherence at 12 months improved by 6-month PrEP dispensing and HIV self-testing among single women in Kenya.

Released: August 5, 2022

VRC01 had no effect on HIV-1 RNA or HIV-1 DNA when given in combination with early ART to infants with HIV.

Released: August 5, 2022

Doxycycline PEP taken within 72 hours of condomless sex resulted in a substantial reduction in the incidence of gonorrhea, chlamydia, and syphilis in this randomized, open-label study.

Released: August 4, 2022

An additional 1 year of unblinded follow-up of the HPTN 084 study continues to support superiority of long-acting injectable CAB vs daily oral TDF/FTC in reducing incident HIV infection among cisgender women at high risk.

Released: August 3, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings